gemcitabine has been researched along with Germinoblastoma in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.14) | 18.2507 |
| 2000's | 16 (38.10) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, X; Fang, Y; Fang, Z; Lin, D; Liu, H; Luo, M; Miao, C; Wu, J; Zhang, X; Zhong, W | 1 |
| An, G; Deng, S; Fu, M; Huang, W; Jiao, Y; Li, R; Liu, H; Liu, W; Lv, R; Qiu, L; Sui, W; Wang, T; Yi, S; Zhao, Y; Zou, D | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
| Altuntaş, F; Bakırtaş, M; Başcı, S; Batgi, H; Baysal, NA; Dal, MS; Darçın, T; İskender, D; Kılınç, A; Kızıl Çakar, M; Merdin, A; Özcan, N; Şahin, D; Uncu Ulu, B; Yiğenoğlu, TN; Yıldız, J | 1 |
| Cordoba, R; Eyre, TA; Luminari, S | 1 |
| Aoki, T; Hayakawa, F; Hikita, T; Iwamoto, E; Kagaya, Y; Kiyoi, H; Kunou, S; Oneyama, C; Sakamoto, A; Sanada, M; Shimada, K; Shimada, S; Takai, M | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Murray, D; Nieto, Y; Valdez, BC | 1 |
| Arai, R; Masatsugu, A; Okuda, H; Sijimaya, T | 1 |
| Bradbury, PA; Chan, KK; Chen, BE; Cheung, M; Cheung, WY; Ding, K; Hay, AE; Kornelsen, EA; Leighl, NB; Mittmann, N; Ng, RCH; Pater, JL; Tu, D | 1 |
| Altuntaş, F; Bozdağ, SC; Demiriz, IŞ; Durgun, G; Koçubaba, S; Sarıca, A; Tekgündüz, E | 1 |
| Asou, H; Kiyosawa, K; Maeda, K; Takeuchi, K; Taniai, H | 1 |
| Blazar, BR; Chandler, P; Ding, ZC; Huang, L; Krasinski, A; Lemos, H; Liu, K; Lu, X; Mack, M; Mellor, AL; Munn, DH; Walters, M; Yu, M; Zhou, G | 1 |
| Aota, Y; Gotoh, A; Komatu, N; Tanaka, M; Tomomatu, J; Watanabe, N | 1 |
| Anthony, S; Babiker, HM; Borad, MJ; Buchbinder, A; Grem, J; Keilani, T; Mita, M | 1 |
| Baetz, T; Chen, BE; Cheung, MC; Couban, S; Crump, M; Desjardins, P; Hassan, S; Hay, AE; Imrie, KR; Kouroukis, CT; Kukreti, V; Le, A; MacDonald, D; Meyer, RM; Mittmann, N; Risebrough, N; Shepherd, L; Song, Y; Sussman, J; Szwajcer, D | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W | 1 |
| Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M | 1 |
| Bowcock, S; De Lord, C; Devereux, S; Dhanapal, V; Fields, P; Gunasekara, M; Kassam, S; Lianwea, C; Marcus, R; Patten, P; Wrench, D; Yallop, D | 1 |
| Arthur, C; Catalano, J; D'Rozario, J; Grigg, A; Leahy, M; Lowenthal, R; Pasricha, SR; Reed, K; Spencer, A; Underhill, C | 1 |
| Galmarini, CM; Myhren, F; Sandvold, ML | 1 |
| Daniels, JT; Garrison, MA; Gjerset, GF; Gooley, TA; Gopal, AK; Lonergan, M; Murphy, AE; Pagel, JM; Petersdorf, SH; Press, OW; Shustov, AR; Smith, JC | 1 |
| Czernin, J; Hacke, K; Hildebrandt, IJ; Kelly, O; Kesner, AL; Lawson, GW; Phelps, ME; Schiestl, RH; Walter, MA; Weber, WA | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Bassett, R; Champlin, R; Chancoco, C; Ciurea, S; Frazier, E; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Thall, P; Valdez, B; Worth, L | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G | 1 |
| Chau, I; Cunningham, D; Watkins, D | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, H; Berlin, JD; Binger, K; Feierabend, C; Marrocha, R; Morgan-Meadows, S; Mulkerin, D; Thomas, JP; Volkman, J; Wilding, G | 1 |
| Archer, CD; Catovsky, D; Chau, I; Cunningham, D; Gill, K; Harries, M; Hill, M; Koh, DM; Norman, AR; Prior, Y; Ross, PJ; Uzzell, M; Wotherspoon, A | 1 |
| Colovos, C; Emmanouilides, C; Hernandez, L; Pinter-Brown, L; Rosen, P; Schiller, G; Territo, M | 1 |
| Bojko, P; Hense, J; Moritz, T; Müller, S; Nowrousian, MR; Schütt, P; Seeber, S | 1 |
| Catovsky, D; Chau, I; Cunningham, D; Hill, M; Horwich, A; Ng, M; Norman, AR; Waters, J; Wotherspoon, A | 1 |
| Carver, JR; Elstrom, R; Glatstein, E; Luger, S; Nasta, SD; Porter, DL; Schuster, SJ; Stadtmauer, EA; Tsai, DE; Vogl, DT | 1 |
| Dexheimer, TS; Fellows, IM; Gleason-Guzman, M; Hurley, LH; Schwaebe, M; Vankayalapati, H; Whitten, JP | 1 |
| Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S | 1 |
| Goldberg, G; Hopkins, U; Rajdev, L; Sparano, JA | 1 |
| Arthur, C; Reed, K; Spencer, A | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
| Wiley, JS | 1 |
| Cheson, BD | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Napieralski, S; Pourebrahim, F; Ries, J; Rummel, MJ; Stein, J; Stieler, M; Weidmann, E | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL | 1 |
3 review(s) available for gemcitabine and Germinoblastoma
| Article | Year |
|---|---|
The use of frailty assessments in treating older adults with aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Disease Management; Doxorubicin; Frailty; Gemcitabine; Geriatric Assessment; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prognosis; Rituximab; Vincristine | 2021 |
[Chemotherapy using gemcitabine hydrochloride for malignant lymphoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Lymphoma; Practice Guidelines as Topic | 2013 |
Gemcitabine and its combinations in the treatment of malignant lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Random Allocation; Recurrence; Rituximab; Transplantation, Autologous; Treatment Outcome | 2002 |
11 trial(s) available for gemcitabine and Germinoblastoma
| Article | Year |
|---|---|
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols | 2015 |
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Niacinamide; Peptides, Cyclic; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2017 |
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Recurrence; Risk; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2008 |
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Patients; Uracil | 2002 |
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hodgkin Disease; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Rate | 2003 |
Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pilot Projects; Racial Groups; Recurrence | 2004 |
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lymphoma; Male; Middle Aged; Time Factors; Treatment Outcome | 2006 |
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting | 2002 |
28 other study(ies) available for gemcitabine and Germinoblastoma
| Article | Year |
|---|---|
Redox-responsive self-assembled polymeric nanoprodrug for delivery of gemcitabine in B-cell lymphoma therapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lymphoma; Lymphoma, B-Cell; Mice; Micelles; Nanoparticles; Neoplasms; Oxidation-Reduction; Polymers; Prodrugs; Tumor Microenvironment | 2022 |
A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2021 |
Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma.
Topics: Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative-Nucleoside Transporter 2; Exosomes; Gemcitabine; Humans; Lymphoma; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Primary Cell Culture; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; DNA Repair; Drug Synergism; Gemcitabine; Humans; Lymphoma; Male; Melphalan; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Tumor Cells, Cultured | 2017 |
Skin Necrosis Due to the Extravasation of Irritant Anticancer Agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Injection Site Reaction; Irritants; Lymphoma; Male; Necrosis; Skin | 2018 |
The economic impact of the transition from branded to generic oncology drugs.
Topics: Antineoplastic Agents; Cetuximab; Cisplatin; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Drug Costs; Drugs, Generic; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphoma; Randomized Controlled Trials as Topic; Vinorelbine | 2019 |
Which regimen is better for stem cell mobilization of lymphoma patients?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Procarbazine; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
Topics: Animals; Antineoplastic Agents, Alkylating; B7-H1 Antigen; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Immunosuppression Therapy; Immunosuppressive Agents; Immunotherapy, Adoptive; Lymphocyte Activation; Lymphoma; Melphalan; Mice; Mice, Inbred BALB C; Myeloid Cells; Programmed Cell Death 1 Receptor; Receptors, CCR2 | 2014 |
[Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Induction Chemotherapy; Lymphoma; Male; Middle Aged; Outpatients; Recurrence | 2015 |
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Cisplatin; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hospital Charges; Hospital Costs; Humans; Lymphoma; Male; Middle Aged; Quality-Adjusted Life Years; Recurrence | 2015 |
Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cladribine; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; Hematopoietic Stem Cell Transplantation; Histones; Humans; Hydroxamic Acids; Intracellular Membranes; Lymphoma; Mitochondria; Signal Transduction; Transplantation Conditioning; Vorinostat | 2016 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult | 2016 |
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Recurrence; Retrospective Studies; Rituximab; Tomography, X-Ray Computed; Young Adult | 2017 |
CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines.
Topics: Cell Line, Tumor; Cell Membrane; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma | 2009 |
Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice.
Topics: Aging; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Disease Progression; Fluorodeoxyglucose F18; Gemcitabine; Image Processing, Computer-Assisted; Lymphoma; Mice; Mice, Knockout; Mitotic Index; Positron-Emission Tomography; Radiopharmaceuticals; Thymus Neoplasms; Tomography, Emission-Computed; Tumor Suppressor Protein p53 | 2010 |
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cytotoxins; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Lymphoma; Melphalan; Protein Serine-Threonine Kinases; Transplantation Conditioning; Transplantation, Homologous; Tumor Suppressor Proteins | 2012 |
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Incidence; Lymphoma; Male; Middle Aged | 2005 |
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.
Topics: Adult; Cardiac Tamponade; Deoxycytidine; Female; Gemcitabine; Heart; Humans; Lymphoma; Male; Mediastinum; Middle Aged; Pericardial Effusion; Radiation Injuries | 2005 |
Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line; Cell Line, Tumor; Deoxycytidine; DNA; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Epoxy Compounds; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Leukemia; Lymphoma; Mice; Mice, Nude; Models, Chemical; Models, Molecular; Pancreatic Neoplasms; Stereoisomerism; Time Factors; Xanthones | 2005 |
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2006 |
Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
New prospects in the treatment of indolent lymphomas with purine analogues.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1998 |
Induction of apoptosis using 2',2' difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic System; Lymphoma; Myeloid Cells | 2000 |